Congressional Letter to Administration on Importance of Animal Biotechnology
October 8, 2021
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our food supply and sustainably meet demand. Ongoing research and existing innovations in animal genetics show great promise in addressing these challenges. However, an efficient, risk and science-based regulatory system that can create a safe, predictable path to market is imperative to capitalizing on these solutions. We believe the existing U.S. regulatory process for the review of animals developed or improved through biotechnology requires significant improvement to meet that standard, and we encourage the U.S. Department of Agriculture (USDA) and Food & Drug Administration (FDA) to continue working with each other and with other relevant federal partners to appropriately modernize this important process.
Download Full Comments Below
Congressional Letter to Administration on Importance of Animal Biotech
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
In response to their advance notice of proposed rulemaking (ANPRM), BIO submitted comments to the DOJ's National Security Division on implementing the White House Executive Order of February 28, 2024, “Preventing Access to Americans’ Bulk Sensitive…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry…
As you know, several challenges facing the agriculture industry and our communities have emerged or intensified in recent years. Zoonotic disease, climate change, and a growing global population require us to consider new solutions to protect our food supply and sustainably meet demand. Ongoing research and existing innovations in animal genetics show great promise in addressing these challenges. However, an efficient, risk and science-based regulatory system that can create a safe, predictable path to market is imperative to capitalizing on these solutions. We believe the existing U.S. regulatory process for the review of animals developed or improved through biotechnology requires significant improvement to meet that standard, and we encourage the U.S. Department of Agriculture (USDA) and Food & Drug Administration (FDA) to continue working with each other and with other relevant federal partners to appropriately modernize this important process.